Streetbeat News

CVKD

Cadrenal Therapeutics, Inc. Common Stock

https://www.cadrenal.com

Industry

Biotechnology

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Cadrenal Therapeutics is set to have a Type-B meeting with the FDA in September to discuss the development of tecarfarin for LVAD patients. This meeting is a significant step towards their pivotal trial.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 1:04 pm

Cadrenal Therapeutics has highlighted a manuscript published in the Journal of Cardiac Failure. The study evaluates the relationship between transthyretin (TTR) management quality and clinical outcomes for patients with left ventricular assist devices (LVAD).

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 1:21 pm

Trading for CVKD has been halted as of 7:50:00 p.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released soon, which could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:50 pm

Cadrenal Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 1:09 pm

Cadrenal Therapeutics (NASDAQ:CVKD) reported a Q2 EPS of $(0.15), missing the analyst consensus estimate of $(0.08) by 87.5%. This represents a 66.67% increase in losses compared to $(0.09) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:35 pm

Cadrenal Therapeutics (NASDAQ:CVKD) and Abbott (NYSE:ABT) are collaborating on a pivotal study of tecarfarin, a novel anticoagulant, for patients with recently implanted LVADs. Tecarfarin aims to prevent heart attacks, strokes, and deaths due to blood clots in these patients.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 1:27 pm

HC Wainwright & Co. has reiterated its Buy rating on Cadrenal Therapeutics (NASDAQ:CVKD) and maintained a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 10:46 am

Cadrenal Therapeutics presented new trial data at the ISHLT Conference, highlighting the importance of anticoagulation quality in LVAD patients. The ARIES-HM3 Clinical Study, sponsored by Abbott, showed that tecarfarin, which recently received Orphan Drug Designation from the FDA, has the potential to improve patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 1:16 pm

The article highlights the performance of 12 health care stocks during Monday's after-market session. Larimar Therapeutics (LRMR) saw the highest gain with a 23.6% increase, while NovaBay Pharmaceuticals (NBY) experienced the largest decline, falling by 9.9%. The article also mentions earnings reports for several companies.

Portfolio Pulse from Benzinga Insights

May 20, 2024 | 8:31 pm

Cadrenal Therapeutics (NASDAQ:CVKD) reported Q1 EPS of $(0.10), missing the consensus estimate of $(0.07) by 42.86%. This represents a 79.17% improvement over the $(0.48) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 4:24 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.